MX379168B - Composición que comprende hidrocortisona. - Google Patents

Composición que comprende hidrocortisona.

Info

Publication number
MX379168B
MX379168B MX2015015759A MX2015015759A MX379168B MX 379168 B MX379168 B MX 379168B MX 2015015759 A MX2015015759 A MX 2015015759A MX 2015015759 A MX2015015759 A MX 2015015759A MX 379168 B MX379168 B MX 379168B
Authority
MX
Mexico
Prior art keywords
hydrocortisone
composition
paediatric
treatment
pharmaceutical compositions
Prior art date
Application number
MX2015015759A
Other languages
English (en)
Spanish (es)
Other versions
MX2015015759A (es
Inventor
Annette Grave
Hiep Huatan
Norbert Poellinger
Richard Ross
Martin Whitaker
Original Assignee
Diurnal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diurnal Ltd filed Critical Diurnal Ltd
Publication of MX2015015759A publication Critical patent/MX2015015759A/es
Publication of MX379168B publication Critical patent/MX379168B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2015015759A 2013-05-17 2014-05-12 Composición que comprende hidrocortisona. MX379168B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1308933.9A GB201308933D0 (en) 2013-05-17 2013-05-17 Paediatric composition
PCT/GB2014/051442 WO2014184525A1 (en) 2013-05-17 2014-05-12 Composition comprising hydrocortisone

Publications (2)

Publication Number Publication Date
MX2015015759A MX2015015759A (es) 2016-03-15
MX379168B true MX379168B (es) 2025-03-10

Family

ID=48746932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015759A MX379168B (es) 2013-05-17 2014-05-12 Composición que comprende hidrocortisona.

Country Status (25)

Country Link
US (1) US9649280B2 (enExample)
EP (1) EP2978414B1 (enExample)
JP (1) JP6371379B2 (enExample)
KR (1) KR102219919B1 (enExample)
CN (1) CN105120848B (enExample)
AU (1) AU2014267041B2 (enExample)
BR (1) BR112015028025B1 (enExample)
CA (1) CA2909060C (enExample)
CY (1) CY1123284T1 (enExample)
DK (1) DK2978414T3 (enExample)
ES (1) ES2813382T3 (enExample)
GB (2) GB201308933D0 (enExample)
HR (1) HRP20201315T1 (enExample)
HU (1) HUE050917T2 (enExample)
IL (1) IL242275B (enExample)
LT (1) LT2978414T (enExample)
MX (1) MX379168B (enExample)
PL (1) PL2978414T3 (enExample)
PT (1) PT2978414T (enExample)
RS (1) RS60734B1 (enExample)
RU (1) RU2664678C2 (enExample)
SI (1) SI2978414T1 (enExample)
SM (1) SMT202000473T1 (enExample)
WO (1) WO2014184525A1 (enExample)
ZA (1) ZA201507210B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
US20190180872A1 (en) * 2017-12-12 2019-06-13 International Business Machines Corporation Second Opinion Decision Support Using Patient Electronic Medical Records
WO2025144994A1 (en) * 2023-12-29 2025-07-03 Regents Of The University Of Minnesota Compositions and methods for intranasal delivery of hydrocortisone
WO2025240605A1 (en) 2024-05-15 2025-11-20 Neurocrine Biosciences, Inc. Combination treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2062634T3 (es) 1990-08-30 1994-12-16 Senju Pharma Co Composicion con liberacion controlada del farmaco.
WO1997025980A1 (en) 1996-01-16 1997-07-24 Advanced Polymer Systems, Inc. Topical delivery of drugs to the lower gastrointestinal tract
KR20040016202A (ko) * 2002-08-16 2004-02-21 주식회사 제이알팜 쓴맛이 차폐된 히드로코르티손 경구용 약제 조성물 및 그제조방법
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
MXPA06012088A (es) 2004-04-22 2007-08-14 Duocort Ab Composiciones farmaceuticas para terapia aguda con glucocorticoides.
RU2382637C2 (ru) * 2004-04-30 2010-02-27 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
ATE474601T1 (de) * 2004-05-31 2010-08-15 Almirall Sa Kombinationen mit antimuskarin-wirkstoffen und pde4-hemmern
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
RU2290940C2 (ru) * 2004-10-18 2007-01-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская Государственная Медицинская академия" МЗ РФ (ГОУ ВПО НижГМА) Средство для коррекции острой почечной недостаточности при токсическом гепаторенальном синдроме, индуцированном четыреххлористым углеродом, и способ коррекции острой почечной недостаточности при токсическом гепаторенальном синдроме, индуцированном четыреххлористым углеродом
AU2006309295B2 (en) * 2005-06-03 2012-04-26 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
EP2120868A4 (en) * 2007-04-11 2010-08-25 Perrigo Israel Phamaceuticals LOW-DOSED MOMETASON FORMULATIONS
GB0817120D0 (en) 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
US20120183610A1 (en) 2009-04-07 2012-07-19 Lennernaes Hans glucocorticoid therapy
DK3403654T3 (da) * 2009-10-01 2019-08-26 Adare Dev I L P Oralt administrerede kortikosteroidsammensætninger
NZ600256A (en) * 2009-12-02 2014-05-30 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
KR20130099815A (ko) 2010-05-20 2013-09-06 듀오코트 파마 아베 글루코코르티코이드에 기초한 조성물의 약량학 및 투여
GB201119985D0 (en) * 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition

Also Published As

Publication number Publication date
EP2978414A1 (en) 2016-02-03
SI2978414T1 (sl) 2020-10-30
CN105120848B (zh) 2019-06-04
HK1214131A1 (zh) 2016-07-22
RU2015150303A (ru) 2017-06-22
IL242275B (en) 2018-08-30
GB201516973D0 (en) 2015-11-11
KR20160011205A (ko) 2016-01-29
PL2978414T3 (pl) 2020-11-16
CN105120848A (zh) 2015-12-02
BR112015028025B1 (pt) 2022-11-29
BR112015028025A8 (pt) 2019-12-31
RU2015150303A3 (enExample) 2018-03-26
NZ712756A (en) 2020-12-18
GB2527233B (en) 2017-07-05
JP2016518439A (ja) 2016-06-23
CA2909060A1 (en) 2014-11-20
US20160081942A1 (en) 2016-03-24
CA2909060C (en) 2020-03-10
EP2978414B1 (en) 2020-07-22
ZA201507210B (en) 2017-07-26
RS60734B1 (sr) 2020-09-30
AU2014267041B2 (en) 2018-11-22
HUE050917T2 (hu) 2021-01-28
PT2978414T (pt) 2020-08-27
SMT202000473T1 (it) 2020-11-10
RU2664678C2 (ru) 2018-08-21
ES2813382T3 (es) 2021-03-23
WO2014184525A1 (en) 2014-11-20
AU2014267041A1 (en) 2015-10-15
DK2978414T3 (da) 2020-08-24
JP6371379B2 (ja) 2018-08-08
US9649280B2 (en) 2017-05-16
GB2527233A (en) 2015-12-16
MX2015015759A (es) 2016-03-15
LT2978414T (lt) 2020-09-25
HRP20201315T1 (hr) 2020-11-27
KR102219919B1 (ko) 2021-02-25
BR112015028025A2 (pt) 2017-07-25
GB201308933D0 (en) 2013-07-03
CY1123284T1 (el) 2021-12-31

Similar Documents

Publication Publication Date Title
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
IL242934B (en) Microbiota restoration therapy (mrt) compounds and methods of manufacture
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX2015013809A (es) Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
SG11201509782TA (en) Compositions and methods for the treatment of diabetes and pre-diabetes
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
CY1123284T1 (el) Συνθεση που περιλαμβανει υδροκορτιζονη
IN2013MU03641A (enExample)
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
IN2013MU03373A (enExample)
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
IN2014DN06808A (enExample)
MX2015016603A (es) Composiciones de corticosteroides.
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
LT2992094T (lt) I tipo diabeto gydymo būdai ir kompozicijos
HK1214131B (en) Composition comprising hydrocortisone
IN2013CH05770A (enExample)
AU2016349439A8 (en) Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of substance use disorders
IN2013CH05769A (enExample)
IN2013MU01983A (enExample)
IN2013CH02437A (enExample)